Generate an explanation for the given claim using the provided supporting material from the paragraph. Please consider the following points while generating an output. 1) The claim will always have supporting proof in the paragraph, and the paragraph will have a clear point of view supporting the claim. 2) There can be instances where direct correlation to the claim is not available. Make use of the sentences in the paragraph to provide a corresponding output supporting the claim. 3) The explanation should be at least one and at most twelve sentences long.

Paragraph: "With abortion now a key issue in the debate over health care reform, abortion rights supporters are highlighting President Barack Obama's promise about the issue during the presidential campaign. In an alert to members on Nov. 9, 2009, Planned Parenthood Action Fund said, ""President Obama campaigned on a promise to put reproductive health care at the center of his reform plan."" We'll address that claim here. We'll also be adding it to our Obameter database of campaign promises. The group's claim is virtually identical to one made in September by House Republican Leader John Boehner, R-Ohio, who said in a statement that, ""during his quest for the presidency, now-President Obama declared that everyone deserves access to reproductive health care that includes abortion, and vowed that this 'right' would be at the heart of his health care reform plan if elected president."" We researched Boehner's claim and concluded he was right about Obama's promise. To explore Obama's promise on abortion coverage in his health care plan, you need to go back to a July 17, 2007, speech he gave to the Planned Parenthood Action Fund. In that speech, he discussed his commitment to how ""reproductive care"" -- a term a campaign aide said included abortion coverage -- would fit into his health care reform plan. Obama said, ""In my mind, reproductive care is essential care. It is basic care, so it is at the center and at the heart of the plan that I propose. Essentially what we're doing is, we’re going to set up a public plan that all persons and all women can access if they don’t have health insurance. It will be a plan that will provide all essential services, including reproductive services, as well as mental health services and disease management services, because part of our interest is to make sure that we’re putting more money into preventive care."" The words Obama used in that speech mirror those in the Planned Parenthood Action Fund's recent alert even more closely than they did Boehner's formulation. So it's certainly correct, as the group says, that Obama ""campaigned on a promise to put reproductive health care at the center of his reform plan."" It's worth nothing that since he spoke to that group -- an important constituency for someone seeking the Democratic nomination -- he has chosen his words carefully. Of all the words Obama has spoken and written about health care reform since 2007 -- a voluminous amount, to be sure -- the terms ""abortion"" and ""reproductive health"" haven't popped up very often. Indeed, on several of the rare occasions in which Obama or his staff have broached the subject, it's been to assure Americans that his health care proposal would not promote abortions. For instance, in his prime-time address to Congress on Sept. 9, 2009, Obama's only mention of abortion -- which came immediately after he was interrupted by the heckling Rep. Joe Wilson, R-S.C. -- was that ""one more misunderstanding I want to clear up: Under our plan, no federal dollars will be used to fund abortions, and federal conscience laws will remain in place."" That's a reflection of the sensitivity surrounding the issue. Obama's promise to the abortion rights group during the primary campaign could now be a liability before a broader audience that includes many people opposed to abortion rights. Still, Planned Parenthood is correct that Obama campaigned on a promise that he would put reproductive health care at the center of his reform plan."" After all, he was speaking to . . . Planned Parenthood. So we find the group's claim to be ." Claim: President Obama campaigned on a promise to put reproductive health care at the center of his reform plan.
"Planned Parenthood says Obama promised to ""put reproductive health care at the center"" of health reform"

Paragraph: The release makes no mention of the cost of the drug in question, Tenofovir. A web search found that the cost for a month’s supply of the antiviral drug averages just over $1,000. For some patients, that cost may be prohibitive. The cost is an issue of particular concern for developing countries, but it is also true that the price may be much lower for them than in the United States. Many pharmaceutical companies offer their drugs at steeply discounted rates in poorer countries to expand access to life-saving medicines. The release clearly says that 68 percent of women receiving the drug reduced their viral load while only 2 percent of the women in the control group had that success. It also says that the transmission of hepatitis B from mother to newborn dropped from 18 percent to 5 percent, an important clinical outcome. The release includes a discussion of harms. It states that “tenofovir was well tolerated; only one participant treated with tenofovir voluntarily withdrew from the study due to nausea.”  It also says that researchers “found no significant differences between the tenofovir-treated group and the control group with regard to fetal development and infant growth.”  Lastly, it calls for longer term, observational studies to confirm the safety of fetal exposure to tenofovir treatment. The release provides a good overview of the randomized, placebo-controlled trial which was undertaken to gauge the efficacy of the drug in both reducing the viral load of hepatitis-B-positive mothers and reducing the rate of transmission of the disease from mother to newborn. It offers solid, numerical evidence of both outcomes. It describes the number of patients (200 pregnant women), defined what constituted a “high” viral load, and described the approximate length of treatment. It did omit a mention of whether the trial was blinded. This release does not commit disease mongering. The release notes that the research is funded by Gilead Sciences. It should also have mentioned that a corresponding author disclosed speaking and advising fees from Gilead, according to the published study. The release is comparing the use of an antiviral drug given to pregnant women versus the normal procedure of giving both a vaccine and immune globulin. The release doesn’t mention that tenofovir (marketed as Viread), the drug being tested, is already an FDA approved drug so many readers may not know that it’s available. It was approved by the FDA in 2001 for HIV and in 2008 for chronic hepatitis B. The release just barely implies novelty with this statement which suggests a change in treating infected women who are pregnant: “Based on the findings, the investigators recommend that women be tested for HBV viral load at week 28 of pregnancy. Those with a high viral load should receive tenofovir treatment starting at gestational week 30 until delivery to reduce the risk of transmission to their infants.” While the drug itself isn’t novel, positive outcomes from a controlled trial on pregnant women carrying the virus does seem to introduce a new treatment approach. This release does not use any unjustifiable language. Claim: Antiviral Treatment During Pregnancy Reduces Mother-to-Child Transmission of Hepatitis B
This news release describes a clinical trial testing whether an antiviral drug given to pregnant women in their third trimester reduces their hepatitis B viral load. The study also examined whether the drug limits the transmission of the virus from mother to baby. The answers to both questions are yes, suggesting a new strategy for dealing with the spread of this disease. The release does a good job describing harms, quantifying benefits and describing the study protocol. Because the cost of hepatitis drugs has been widely debated for the past few years, a mention of the drug’s cost would have made the release stronger. Almost 240 million people are infected with hepatitis B virus and about 780,000 die each year from the disease, according to the World Health Organization. The hepatitis B virus infects the liver and while many recover with treatment, it can become a chronic infection. Babies and young children infected with the virus are more likely to develop chronic hepatitis B. If administering a drug to infected mothers reduces the proportion of newborns getting the disease, it would be a considerable improvement in public health.

Paragraph: Japanese cases topped 2,000, and public broadcaster NHK said 78 cases in Tokyo took its tally of infections past 500. Media reports said 7 people in the city had died, five at one hospital. “This is the greatest increase up to now and is certainly of high concern, and I’m worried about what tomorrow’s figures might show,” Tokyo Governor Yuriko Koike said. A government spokesman said Prime Minister Shinzo Abe told cabinet members he and his second-in-command, Taro Aso, would no longer attend the same meetings to protect the leadership from infection. But the two were later shown at the same gathering - although wearing masks and sitting apart. Last week, British Prime Minister Boris Johnson was obliged to switch to running the country from isolation after testing positive for the virus. Economy Minister Yasutoshi Nishimura said Japan was not yet in a situation that required a state of emergency, triggering a potential lockdown, although the situation was precarious. “We’re just barely holding it together,” Nishimura told reporters. “If we loosen our grip even a little, it wouldn’t be surprising to see a sudden surge.”  Infections have now exceeded 770,000 worldwide, with more than 37,000 deaths, as confirmed cases in the United States, Italy and Spain overtake mainland China, where the virus originated late last year. In Tokyo, there has been intense speculation that a lockdown could come soon, fueled by the rising number of cases. The national total edged past 2,000 infections after a center for disabled people in Chiba prefecture, east of Tokyo, found seven more infections. There have been 66 deaths. With limited testing in Japan, there are questions about how widely the virus has spread. About 7.1% of nearly 64,000 respondents said they had at least one virus symptom, such as high fever or a bad cough, between Friday and Monday, according to a survey of users in Tokyo and neighboring prefectures run by the chat app Line (3938.T) and the health ministry. Such symptoms do not by themselves prove infection. But the 4,500 people who reported symptoms in the survey was markedly higher than Tokyo’s official figure of 443 infections by Monday. Only last Tuesday, with a lockdown already in the offing, Japan and Olympic authorities gave in to pressure from athletes and sporting bodies worldwide to delay Tokyo’s 2020 Summer Games for a year. Some businesses in the capital are moving to curtail operations even ahead of a lockdown. On Tuesday, department store operator Isetan Mitsukoshi Holdings Ltd (3099.T) said it would close six stores in Tokyo on weekends through April 12. Koshidaka Holdings (2157.T), an operator of karaoke and hot spring outlets, said it would close 200 karaoke outlets until April 13. But any lockdown in Japan would look different from mandatory measures in some parts of Europe and the United States. Laws limit local authorities to requesting people to stay at home. Tokyo Governor Koike has asked residents to avoid unnecessary outings, while her counterpart in the second biggest city of Osaka felt the government should declare a state of emergency, media said. The government said it would seek data from wireless carriers, such as statistics on people’s movements, to help gauge the effectiveness of a voluntary request. A director of Japan’s top organization of doctors urged that an emergency be declared before it was too late. Development of medicines and vaccines would be crucial to contain the virus, Abe told Tedros Adhanom Ghebreyesus, director general of the World Health Organization, in a telephone call on Monday. Japan intends to promote clinical research on an anti-flu medicine called Favipiravir with other countries as a treatment, Abe said. The drug, also known as Avigan, was developed by Fujifilm Holdings Corp (4901.T), shares of which closed up 2.2%, after having risen as much as 6.6% in Tokyo. The company later said in a statement it was starting a Phase III clinical trial in Japan of the drug for the coronavirus. (Graphic: Tracking and explaining the new coronavirus, here) Claim: Tokyo records most new coronavirus cases in a day as pressure for lockdown builds.

Japan’s capital recorded more than 70 new coronavirus infections on Tuesday for its highest tally in a single day, as pressure mounted on the prime minister to order a lockdown.